Retinal implant offers rudimentary sight to blind

Article

Second Sight's "bionic eye" implant, the Argus II Retinal Prosthesis System, has been implanted into two blind patients at London's Moorfields Eye Hospital by Dr Lyndon da Cruz and team.

Second Sight's "bionic eye" implant, the Argus II Retinal Prosthesis System, has been implanted into two blind patients at London's Moorfields Eye Hospital by Dr Lyndon da Cruz and team. The patients were the first British subjects of a multinational Phase I clinical trial, being conducted in Britain, the US and Mexico.

The implant is designed to combat retinitis pigmentosa (RP). Sixty electrodes, which conduct information acquired from an external camera to the retina, provide a rudimentary form of sight (motion and light and dark) to implanted subjects. The first generation of the implant, the Argus 16, comprised 16 electrodes and was tested in six RP patients between 2002 and 2004; the next generation device, currently under development, will have 1000 electrodes, allowing facial recognition.

Four more subjects have been recruited into the US arm of the trial. If the trials go well, it is hoped that the implant will be widely available within five years.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.